{"created":"2023-05-15T09:06:28.535639+00:00","id":13173,"links":{},"metadata":{"_buckets":{"deposit":"cb3e4810-3f68-431b-91c1-1e3ea84576ec"},"_deposit":{"created_by":14,"id":"13173","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"13173"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00013173","sets":["1875:1909:1997"]},"author_link":["20040","20041"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-07-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"11","bibliographicPageStart":"7","bibliographicVolumeNumber":"20","bibliographic_titles":[{"bibliographic_title":"名寄市立病院医誌 = The Jounal of Nayoro City Hospital"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"リセドロネートは第3世代のビスフォスフォネート系骨粗鬆症治療剤で骨粗鬆症の予防と治療ガイドライン2011年版でも第2世代のアレンドロネートと並んで骨密度、椎体骨折、非椎体骨折、大腿骨近位部骨折に対する有効性についてグレードAの高い評価を得ている1)。第3世代のリセドロネートは第2世代のアレンドロネートよりもその効果が優ることが期待された。この2剤の同一医療施設においての報告はあまり認められず、今回当院において、アレンドロネート、ミノドロン酸水和物の報告に引き続いて、リセドロネートの治療効果を調べたので報告する。また3年間の治療経過から、薬剤の効果減弱について検討し、さらに薬剤変更の時期について検討を加えて報告する。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"名寄市立総合病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1340-2749","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"坂田, 仁"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"京極, 元"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"n134027492017.pdf","filesize":[{"value":"985.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"n134027492017.pdf","url":"https://sapmed.repo.nii.ac.jp/record/13173/files/n134027492017.pdf"},"version_id":"4253140c-02d0-4a65-8121-29f4029f5783"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"リセドロネート17.5mg、","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"骨粗鬆症","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"DXA","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"骨密度測定","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"尿中NTX","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"週1回投与製剤リセドロネート17.5mgによる骨粗鬆症の治療効果","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"週1回投与製剤リセドロネート17.5mgによる骨粗鬆症の治療効果","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1997"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2015-03-21"},"publish_date":"2015-03-21","publish_status":"0","recid":"13173","relation_version_is_last":true,"title":["週1回投与製剤リセドロネート17.5mgによる骨粗鬆症の治療効果"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T04:01:42.744387+00:00"}